Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101
Current TAP Partner
PHILADELPHIA, Dec. 19, 2024 - Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company specializing in the development of innovative cell therapies for hard-to-treat diseases, today announced that in November, the first patient was dosed in its Phase 1 clinical trial of VIPER-101. VIPER-101 is an enabled autologous cell therapy designed to treat relapsed and/or refractory (r/r) T cell lymphoma, a severe disease with limited treatment options.
The open-label Phase 1 study is designed to assess safety and preliminary efficacy, and to determine the recommended Phase 2 dose (RP2D) of VIPER-101 in patients with r/r CD5 positive nodal T cell non-Hodgkin lymphoma (NHL). The study is currently recruiting patients and additional information can be found at ClinicalTrials.gov (NCT06420089).
The Company anticipates preliminary data from the trial in 2025.